WO1999000394A1 - Calixarene tubes as cation receptors - Google Patents

Calixarene tubes as cation receptors Download PDF

Info

Publication number
WO1999000394A1
WO1999000394A1 PCT/GB1998/001854 GB9801854W WO9900394A1 WO 1999000394 A1 WO1999000394 A1 WO 1999000394A1 GB 9801854 W GB9801854 W GB 9801854W WO 9900394 A1 WO9900394 A1 WO 9900394A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
compound according
same
group
Prior art date
Application number
PCT/GB1998/001854
Other languages
French (fr)
Inventor
Philippe Schmitt
Paul Derek Beer
Original Assignee
The Secretary Of State For Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Secretary Of State For Defence filed Critical The Secretary Of State For Defence
Priority to US09/446,458 priority Critical patent/US6326394B1/en
Priority to JP50537599A priority patent/JP2001515515A/en
Priority to EP98930943A priority patent/EP0993462B1/en
Priority to DE69810294T priority patent/DE69810294T2/en
Priority to AT98930943T priority patent/ATE229959T1/en
Priority to GB9927551A priority patent/GB2342351B/en
Publication of WO1999000394A1 publication Critical patent/WO1999000394A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Definitions

  • the present invention relates to molecules which are specific for certain cations, such as potassium or caesium, to their preparation and their uses for example as reagents in reactions requiring a cation scavenging agent.
  • the molecules of the invention which are specific for potassium ions may also be regarded as mimicing potassium ion channels
  • Potassium channel proteins have been the subject of an intense investigation this last decade and a great deal of information about their structure/function relationships has been elucidated (e.g: C. Miller, Science 1991 , 252, 10921096 (re-view) , J.O.Dolly, et al., J. Bioenerg. Biomembr. 1996, 28, 231-253; Q L ⁇ et al., Science 1995, 268, 304-307 ; P. Hidalgo et al.. Science 1995, 268, 307-310; J.
  • the channel pore region responsible for the crucial alkali-metal selection contains a square planar array of four converging tyrosine residues (e.g. R. Ranganathan et al., Neuron 1996, 16, 131-139; L. Heginbotham et al., Biophys. J. 1994, 66, 1061-1067; S. Bogusz et al . , Protein Eng. 1992, 5, 285- 293) .
  • a proposed selection mechanism supported by experimental and ab ini tio studies, suggests that an en face cation- ⁇ interaction between the potassium and the aromatic surfaces of the tyrosines could be determinant for such a unique selectivity pattern (D. A.
  • R x groups which may be the same or different are selected from
  • n is an integer of from 2-6:
  • R y and R groups which may be the same or different are independently selected from hydrogen, halogen or an optionally substituted hydrocarbyl group;
  • R° together with R b of the adjacent phenyl ring and R c together with R ⁇ of the adjacent phenyl ring form a group of formula -(CH,),,,- or -0- (CH 2 ) -O- where m and p are integers of from 1-5, and each group R a -R and R c -R d may be the same or different; and x is an integer of 4 or more.
  • x is an integer of from 4-8.
  • the precise number of x will depend upon the ion which the compound of formula (I) is intended to be specific for.
  • x is suitably 4, but for caesium a higher value, for example 5 may be preferred.
  • the invention provides a compound of formula
  • R 1 , R 2 , R 3 , R 4 , R 5 , R ⁇ , R 7 and R 8 are independently selected from hydrogen, halogen, or an optionally substituted hydrocarbyl group;
  • R 3 , R 10 , R u and R 12 are independently selected from -O- (CH 2 ) n -0- where n is an integer of from 2-6;
  • R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 are independently selected from - (CH.) - or -O- (CH ) -O- where m and p are integers of from 1-5.
  • Suitable hydrocarbyl groups for R y , R ⁇ R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 include hydrocarbyl groups containing from 1 to 20 carbon atoms including straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl, aryl groups or aralkyl groups.
  • the term 'aryl' includes phenyl and naphthyl groups.
  • the term "aralkyl” includes C ⁇ alkylaryl such as benzyl.
  • Suitable optional substitutents for hydrocarbyl groups include functional groups such as ether or ester groups, in particular alkyl ether or ester groups.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same group, in particular C h alky1 groups such as methyl, ethyl, propyl or n- ojr tert-butyl, most preferably tert -butyl.
  • R , R , R and R are the same and n is 2.
  • R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 are the same group, in particular an alkylene group where m is 1.
  • p is 1.
  • R y , R a , R b and x are as defined in relation to formula (I) , and and R 21 groups are the same or different and are selected from -O- (CH, 2)' n-O-R 22 where R 22 is a leaving group such as tosylate or mesylate;
  • R z , R c , R d and x are as defined in relation to formula (I); in the presence of a base.
  • Suitable bases include weak bases such as carbonates, in particular alkali metal carbonates such as potassium carbonate.
  • the reaction is effected in the presence of an organic solvent such as acetonitrile.
  • Compounds of formula (III) and (IV) are either known compounds or they can be prepared from known compounds by conventional methods.
  • the compounds of the invention may also be utilised as ion selective electrodes which select specifically particular ions such as potassium ions. Such electrodes form a further aspect of the invention.
  • the compounds of formula (I) can be used as a reagent in chemical reactions and processes where cation scavenging is required.
  • Such reactions include the purification of analar salts of alkali and alkaline earth metals. For instance, contact of sodium, lithium and caesium salts with compound of formula (II) will result in the removal of contaminating potassium ions.
  • compounds of formula (I) may act as phase transfer catalysts. Addition of compounds of formula (I) to organic synthesis reactions may result in the solubilisation of specific salts.
  • Figure 1 is an ORTEP view of a compound of the invention (compound VII) based on X-ray crystal structure analysis;
  • Figure 2 shows * H NMR spectrum of compound VII [500MHz, CDC1 3 -CD 3 0D 4/1 (v/v) ] : a) pure compound VII, b) with 10 equivalent of solid potassium iodide (c,m: solvent peaks corresponding respectively to chloroform and methanol) ;
  • the measurements were made by relative integration of the corresponding ⁇ -NMR spectra after 90 hours (3.7 days) of standing. In the case of KI, equilibrium was reached within an hour;
  • Figure 4 is an ORTEP view of compound (VIII) which is the potassium complex of compound VII based on X-ray crystal structure analysis
  • Figure 5 is a schematic representation of the potassium uptake of compound VII based on molecular dynamics calculations.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • External Artificial Organs (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Catalysts (AREA)

Abstract

A cyclic compound of formula (I) wherein Rx groups which may be the same or different are selected from -O-(CH¿2?)n-O- where n is an integer of from 2-6; R?y and Rz¿ groups which may be the same or different are independently selected from hydrogen, halogen or a hydrocarbyl group; Ra together with Rb of the adjacent phenyl ring and Rc together with Rd of the adjacent phenyl ring form a group of formula -(CH¿2?)m- or -O-(CH2)p-O- where m and p are integers of from 1-5, and each group R?a-Rb and Rc-Rd¿ may be the same or different; and x is an integer of 2 or more, such as 4. Compounds of formula (I) display particular selectivity for specific ions such as potassium ions. They are useful inter alia in reactions where scavenging of a specific cation is required or as ion specific electrodes.

Description

CALIXARENE TUBES AS CATION RECEPTORS
The present invention relates to molecules which are specific for certain cations, such as potassium or caesium, to their preparation and their uses for example as reagents in reactions requiring a cation scavenging agent. The molecules of the invention which are specific for potassium ions may also be regarded as mimicing potassium ion channels
Potassium channel proteins have been the subject of an intense investigation this last decade and a great deal of information about their structure/function relationships has been elucidated (e.g: C. Miller, Science 1991 , 252, 10921096 (re-view) , J.O.Dolly, et al., J. Bioenerg. Biomembr. 1996, 28, 231-253; Q Lύ et al., Science 1995, 268, 304-307 ; P. Hidalgo et al.. Science 1995, 268, 307-310; J.
Aiyar, et al.. Neuron 1995, 15, 1169-1181; M. Stocker et al., Proc. Natl. Acad. Sci. USA 1994, 91, 9509-9513; J.C.Bradley et al . , Protein Eng. 1993, 7, 859-862). A very exciting aspect, still controversial, focuses on how these proteins transport potassium through the cell membrane, with high rates and almost perfect selectivity (K+ transported 1000 times more efficiently than Na+) (G. Yellen, J.Gen. Physiol. 1984, 84, 157; J. Neyton et al . J. Gen. Phvsiol. 1988, 92, 569) .
The channel pore region responsible for the crucial alkali-metal selection, termed the selection filter, contains a square planar array of four converging tyrosine residues (e.g. R. Ranganathan et al., Neuron 1996, 16, 131-139; L. Heginbotham et al., Biophys. J. 1994, 66, 1061-1067; S. Bogusz et al . , Protein Eng. 1992, 5, 285- 293) . A proposed selection mechanism, supported by experimental and ab ini tio studies, suggests that an en face cation-π interaction between the potassium and the aromatic surfaces of the tyrosines could be determinant for such a unique selectivity pattern (D. A. Dougherty, Science 1996, 272, 163-168; C. Miller, Science 1993, 261, 1692-1693 ; L. Heginbotham, et al . , Neuron 1992, 8, 483-491 ; J. Sunner et al., J. Phys . Chem. 1981, 85, 1814-1820).
Despite the involvement of numerous research groups in the development of synthetic channels (reviewed by G. . Gokel et al., Ace. Chem. Res. 1996, 29, 425-432; K. S . Akerfeldt et al . , Acc- Chem. Res. 1993. 26, 191-197, a biomimetic approach focusing in particular on the alkali -metal selection process has not previously been fully investigated. In an effort to accredit the cation-π hypothesis, a novel biomimetic calix[4] arene based tubular receptor whose access to metal cations may be controlled by filtering gates based on a square planar array of aromatic surfaces was designed.
According to the present invention, there is provided a cyclic compound of formula (I)
Figure imgf000004_0001
wherein Rx groups which may be the same or different are selected from
-0-(CH2)n-0- or -0- (CH2CH20)n- where n is an integer of from 2-6:
Ry and R groups which may be the same or different are independently selected from hydrogen, halogen or an optionally substituted hydrocarbyl group;
R° together with Rb of the adjacent phenyl ring and Rc together with Rά of the adjacent phenyl ring form a group of formula -(CH,),,,- or -0- (CH2) -O- where m and p are integers of from 1-5, and each group Ra-R and Rc-Rd may be the same or different; and x is an integer of 4 or more.
Suitably x is an integer of from 4-8. The precise number of x will depend upon the ion which the compound of formula (I) is intended to be specific for. In the case of potassium, x is suitably 4, but for caesium a higher value, for example 5 may be preferred.
Thus in a preferred embodiment, the invention provides a compound of formula
Figure imgf000005_0001
where R1, R2, R3, R4, R5, Rδ, R7 and R8 are independently selected from hydrogen, halogen, or an optionally substituted hydrocarbyl group;
R3, R10, Ru and R12 are independently selected from -O- (CH2)n-0- where n is an integer of from 2-6;
R13, R14, R15, R16, R17, R18, R19 and R20 are independently selected from - (CH.) - or -O- (CH ) -O- where m and p are integers of from 1-5.
Suitable hydrocarbyl groups for Ry, R\ R1, R2, R3, R4, R5, R6, R7 and R8 include hydrocarbyl groups containing from 1 to 20 carbon atoms including straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl, aryl groups or aralkyl groups. As used herein, the term 'aryl' includes phenyl and naphthyl groups. The term "aralkyl" includes C^alkylaryl such as benzyl. Suitable optional substitutents for hydrocarbyl groups include functional groups such as ether or ester groups, in particular alkyl ether or ester groups.
Preferably R1, R2, R3, R4, R5, R6, R7 and R8 are the same group, in particular Chalky1 groups such as methyl, ethyl, propyl or n- ojr tert-butyl, most preferably tert -butyl.
Suitably R , R , R and R are the same and n is 2.
Suitably R13, R14, R15, R16, R17, R18, R19 and R20 are the same group, in particular an alkylene group where m is 1.
Preferably p is 1.
Compounds of formula (I) are suitably prepared by reacting a compound of formula (III)
Figure imgf000006_0001
where Ry, Ra, Rb and x are as defined in relation to formula (I) , and and R21 groups are the same or different and are selected from -O- (CH, 2)' n-O-R22 where R22 is a leaving group such as tosylate or mesylate;
with a compound of formula (IV)
Figure imgf000006_0002
where Rz, Rc, Rd and x are as defined in relation to formula (I); in the presence of a base.
Suitable bases include weak bases such as carbonates, in particular alkali metal carbonates such as potassium carbonate. Suitably the reaction is effected in the presence of an organic solvent such as acetonitrile.
Compounds of formula (III) and (IV) are either known compounds or they can be prepared from known compounds by conventional methods.
For example, the template-driven condensation of p-tert-butyl- calix[4]arene (VI) with a per-tosylated derivative of formula (V) in acetonitrile, in presence of potassium carbonate, furnished the novel calix[4]tube (VII) in fairly good yields (51% isolated yields, Scheme 1).
Figure imgf000007_0002
Figure imgf000007_0001
Sc r- M
Compounds of formula (I) combine several appealing features that make them a suitable model system of relevance for the design of new selective ion channels in particular potassium selective ion channels as illustrated hereinafter. They may be utilised in an in vitro screen, where compounds which have an effect on potassium ion channels would be of assistance. in addition, the effects on cell membranes may mean that compounds of formula (I) display antibiotic properties .
Moreover, the amazing potassium selectivity displayed by compound VI, allied with the biomimetic design of its cation-accessing gates, tend to accredit the cation filtering role occupied by the fourfold symmetrical array of aromatic residues at the narrower portion of naturally occurring channels. The distance separating the two- cofacial phenyl rings in compound VI (5.88A) is very close to the corresponding distance, predicted by ab initio calculations, in a hypothetical cation-π complex - (bis -η6-arene) made of two benzene rings and a potassium ion (5. 84A) ( R. A- Kumpf, D. A. Dougherty, Science 1993, 261, 1708-1710). This raises the question as to whether such a transient species between compound VII and K+, may be responsible for the very original binding behaviour observed.
These properties mean that the compounds of the invention may also be utilised as ion selective electrodes which select specifically particular ions such as potassium ions. Such electrodes form a further aspect of the invention.
In addition, the compounds of formula (I) can be used as a reagent in chemical reactions and processes where cation scavenging is required. Such reactions include the purification of analar salts of alkali and alkaline earth metals. For instance, contact of sodium, lithium and caesium salts with compound of formula (II) will result in the removal of contaminating potassium ions.
Furthermore, compounds of formula (I) may act as phase transfer catalysts. Addition of compounds of formula (I) to organic synthesis reactions may result in the solubilisation of specific salts.
The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings in which
Figure 1 is an ORTEP view of a compound of the invention (compound VII) based on X-ray crystal structure analysis;
Figure 2 shows *H NMR spectrum of compound VII [500MHz, CDC13-CD30D 4/1 (v/v) ] : a) pure compound VII, b) with 10 equivalent of solid potassium iodide (c,m: solvent peaks corresponding respectively to chloroform and methanol) ;
Figure 3 shows the results of monitoring the metallic untake of compound VI by treating its chloroform-methanol solution (4/1, compound VII=lmM) with 10 equivalents of alkali -metal iodide. The measurements were made by relative integration of the corresponding ^-NMR spectra after 90 hours (3.7 days) of standing. In the case of KI, equilibrium was reached within an hour;
Figure 4 is an ORTEP view of compound (VIII) which is the potassium complex of compound VII based on X-ray crystal structure analysis; and
Figure 5 is a schematic representation of the potassium uptake of compound VII based on molecular dynamics calculations.
Example 1
Preparation of Potassium Ion Selective Calixarene A suspension of p- tert-butyl -calix [4] arene (451 mg, 0.70mmol) and potassium carbonate (480 mg, 3.5mmol) in 100ml of dry acetonitrile was stirred under nitrogen. After 2 hours at room temperature, compound V (lg, 0.70 mmol) was added and the reaction mixture brought to reflux for 5 davs . The solvent was then removed in vacuo and the solid suspended in a 1:1 ethanol -water mixture. The suspension was refluxed overnight and hot filtered. The crude mixture was then dissolved in 50ml of chloroform and carefully paper filtered to yield a clear solution to which 40ml of acetone was added. The filtration of the microcrvstalline material obtained after a few hours of standing, followed by its drying in vacuo yields 500 mg of compound VII as an analytically pure product (51%) .
Η NMR (500 MHz, CDC13) : δ = 7.09 (s, 8H, HI/HI'), 6.48 (s, 8H", HI/HI'), 5.15 (s, 8H, H2/H2'), 4.57 (d, j=13 Hz, 8H, H3), 4.39 (s, 8H, H2/H2'), 3.25 (d, j=13 Hz, 8H, H4) , 1.31 (s, 36H, H5/H5'), 0.80 (s, 36H, HS/H5') ; "C NMR (125 MHz, CDC13) : δ=15c5.0 (Cl/Cl') , 152. 8
(Cl/Cl') , 144.5 (C2/C21) , 144.3 (C2/C2 ' ) , 135.1 (C4/C4') , 131.9 (C4/C4') , 125.5 (C3/C3') , 124.8 (C3/C3 ' ) , 73.0 (C5/C51) , 72.5 (C5/C51) , 34.1 (C6/C61) , 33.5 (C6/C6 ' ) , 32.4 (C8) , 31.7 (C7/C7') , 31.0 (C7/C7.1) ; C,H,C1 -analysis (C96H120Oa.CHCl3) : calc. C 76.58, H 8.02, Cl 6.99; found C 76.32, H 8.17, Cl 8.09.
Surprisingly the compound of formula (VII) was found to be insoluble in all common organic solvents with the exception of chloroform and carbon tetrachloride. Crystallized from a chloroform/benzene mixture, compound (VII) was submitted to crystal structure analysis (Figure 1) and found to exhibit a Ci symmetry in the solid state. The crystal structure data is as follows:
Triclinic, P 1, a = 10.286(12), b=14.803 (14) , c=19.01(2) A, α = 75,705(10),β = 83.663(10), γ = 64.910(10)°, V = 2541 (5) A, z = 1, λ(MoK0) = 0.71073 A, T = 293(2)°K. 7510 independent reflections were measured on a MARresearch Image Plate up to 2θ = 25.09°. Data analysis was carried out with the XDS program (...). The structure was solved with directs methods and anisotropically refined on F2 (program SHELX-86, G. M. Sheldrick, Universitat Gδttingen) .
It contains two identical flattened calix [4] arene units each of which consists of two almost parallel, and two almost perpendicular phenyl rings. It is noteworthy that the ethylene linkages alternate in two different geometries. Two of them present an anti-like conformation (O-C-C-0 torsion angle of 162.2° whereas the remaining two display a gauche- type conformation (O-C-C-0 torsion angle of 47.8°. As a consequence of this particular arrangement, the central eight oxygen cage is unsuitable to form an inclusion complex.
Interestingly, on the NMR time- scale, this conformational symmetry was mostly conserved in solution. Dissolved in deuterated chloroform, compound (VII) exhibited both 'H and 1C NMR spectra consistent with the freezing of the calixarenes in their-flattened cone conformation. With the exception of the methylene related peaks, all the signals were found split in two sinσlets of equal intensity. Moreover, up to 55°C the ^-NMR spectra were found to be temperature independent. The absence of any coalescence or even peak broadening, features indicative of a time-averaged D4h symmetry, suggests that a calix [4] tube is an extremely rigid molecule in solution. As a consequence of the solubility limitations of compound VII, a deuterated chloroform-methanol (8:2) mixture was employed for the NMR-based metal cation complexation studies. To 1ml of compound VII in this solvent mixture (lmM) at 25°C was added lOμmol (10 equivalents of solid alkali -metal iodide. The samples were sonicated briefly and ^-NMR spectra were recorded at various times.
Example 2 Reaction with alkali metals
A chloroform-methanol solution (4/1, compound VII = ImM) with 10 equivalents of various alkali metal iodides. Treated with potassium iodide, compound VII underwent a dramatic change to a potassium complex compound VIII. Within the first hour upon mixing the initial spectrum disappeared below detection and was replaced by a new set of peaks suggestive of an increase of the ligand symmetry (figure 2) . The structural degeneracy of compound VII, characterized by a fourfold symmetry along the molecule's main axis, is consistent with the opening of the binding cavity driven by the complexation of potassium cation within the eight oxygen- cage.
Analogous experiments with other alkali -metal iodides (Lil, Nal, Rbl and Csl) failed to exhibit any significant cation uptake. Estimated by relative integration, less than 7% of compound VII was complexed after more than three days in presence of 10 equivalents of Rbl.
This ratio dropped below 5% in the cases of Lil, Nal and Csl (figure 3) . Although synthetic ionophores displaying a high potassium selectivity are known (E. Ghidini et al . , J. Am. Chem. Soc. 1990, 112, 6979-6985 ; A- M. King et al., J. Chem. Soc. Chem. Commun. 1992, 582-584) such a remarkable preference for potassium over any of the alkali -metals is unprecedented for a synthetic receptor.
Example 3
Investigation of potassium complexation In order to investigate the potassium complexation process quantitatively, the uptake of lμ ol of KI ( [Kl] = 10-3 M) by one equivalent of compound VII, in homogeneous solution at 25°C, was monitored as a function of time. After 24 hours the system was evaluated to have reached equilibrium (86% of compound VI was complexed), the formation of a 1:1 complex was established and a stability constant of 4X104 L mol-1 was estimated. The complexation halftime, defined by the time necessary for the system to reach half the equilibrium conversion ratio, was measured to be 18 minutes. Although these are preliminary results, this experiment reveals the complexation process is kinetically slow and may be a consequence of an important intramolecular reorganization necessary for the cation uptake.
Comparison of the chemical shifts values of compound VII and of its potassium complex, shows in general low-field shift deviations of all the calix[4]arene-related signals (Δδ tert-butyl :+ 0.923 ppm, phenyl: +0.426 ppm, methylene: +0.216 ppm), whilst the ethylene protons exhibit an average high field variation in their corresponding signals (-0.228 ppm, figure 2). This feature is consistent with a displacement of the ligand electron density towards the molecule's equatorial plane caused by the close proximity of the complexed metal positive charge.
The geometry of the complex VIII was confirmed by X-Ray analysis. As predicted by NMR, compound VIII is highly symmetrical and contains a C4 along the main axis of the molecule (D4 point group) . The potassium atom is located at the centre of a slightly flattened cube at an average distance of 2.78A from all oxygen atoms (Figure 4) .
Example 4
Molecular Dynamics Studies
Of relevance to potassium selective channel transportation, it is worthwhile speculating as to how the potassium cation enters the oxygen cage cavity of calix[4] tube. Examination of both solid-state structures suggests that thecalix[4] arene macrocycles would form the main accesses to the potassium-binding site (Figure 5) . Even though known for monomeric cali [4] arenes, (P. Guibauld, et al . , J. Am. Chem. Soc. 1993, 115, 8298-8312) this assumption was verified in the particular case of compound VII by ah initio molecular dynamics
(Quanta, CHARMM version 23.1, Molecular Simulations Inc., Cambridge UK, San Diego California USA) . Preliminary modellings suggested indeed that the complexation of potassium would require an activation energy 10 to 15 kcal mol'1 larger by accessing the cavity across rather than along the main axis.

Claims

Claims
A cyclic compound of formula (I)
Figure imgf000013_0001
wherein Rx groups which may be the same or different are selected from
-O- (CH2)n-0- or -0- (CH2CH20)n- where n is an integer of from 2-6:
Ry and Rz groups which may be the same or different are independently selected from hydrogen, halogen or an optionally substituted hydrocarbyl group;
R" together with Rb of the adjacent phenyl ring and Rc together with Rd of the adjacent phenyl ring form a group of formula - (CH_)m- or -0- (CH2) -0- where m and p are integers of from 1-5, and each group Ra-Rb and Rc-Rli may be the same or different; and
x is an integer of 2 or more.
2. A compound according to claim 1 wherein x is an integer of from 4-8.
3. A compound according to claim 1 or claim 2 of formula (II)
Figure imgf000014_0001
where R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, halogen, or a hydrocarbyl group;
R9, R10, R11 and R12 are independently selected from -0-(CH2)n-0- where n is an integer of from 2-6;
R , R , R , R , R , R , R and R are independently selected from -(CH2)m- or -0- (CH2) -0- where m and p are integers of from 1-5.
4. A compound according to claim 3 wherein R1, R2, R3, R , R , R , R and R8 are the same group.
5. A compound according to claim 3 or claim 4 wherein R1, R2, R , R4, R5, R6, R7 and R8 are C1-6 alkyl groups.
6. A compound according to claim 5 wherein R1, R2, R3, R , R , R , R and R8 are tert -butyl.
7. A compound according to any one of claims 3 to 6 where R9, R10,
R11 and R12 are the same and n is 2 ,
8. A compound according to any one of claims 3 to 7 wherein R13, R14, R15, Rl╬┤, R17, R18, R19 and R20 are the same group.
9. A compound according to claim 8 wherein R13, R14, R15, R16, R17, R18,
R9 and R are -CH2- or -0CH.0-
10. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 9 which process comprises reacting a compound of formula (III)
Figure imgf000015_0001
where Ry, Ra, Rb and x are as defined in relation to formula (I) , and and R21 groups are the same or different and are selected from -0- (CH2)n-0-R22 where R22 is a leaving group such as tosylate or mesylate; with a compound of formula (IV)
Figure imgf000015_0002
where Rz, Rc Rd and x are as defined in relation to formula (I); in the presence of a base.
11. An antibiotic comprising a compound of formula (I) as claimed in any one of claims 1 to 9 which displays antibiotic properties.
12. An ion selective electrode comprising a compound as claimed in any one of claims 1 to 9.
13. A method of purifying salts of alkali and alkali metals which comprises contacting said salt with a compound of formula (I) which is specific for a different cation.
14. A phase transfer catalyst comprising a compound according to any one claims 1 to 9.
15. A method of solubilising a particular salt in an organic synthesis reactions, which comprises adding to the reaction mixture a compound according to any one of claims 1 to 9.
PCT/GB1998/001854 1997-06-25 1998-06-24 Calixarene tubes as cation receptors WO1999000394A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/446,458 US6326394B1 (en) 1997-06-25 1998-06-24 Calixarene tubes as cation receptors
JP50537599A JP2001515515A (en) 1997-06-25 1998-06-24 Calixarene tubes that are cation acceptors
EP98930943A EP0993462B1 (en) 1997-06-25 1998-06-24 Calixarene tubes as cation receptors
DE69810294T DE69810294T2 (en) 1997-06-25 1998-06-24 CALIXAREN TUBES AS CATION RECEPTORS
AT98930943T ATE229959T1 (en) 1997-06-25 1998-06-24 CALIXARENE TUBES AS CATION RECEPTORS
GB9927551A GB2342351B (en) 1997-06-25 1998-06-24 Calixarene tubes as cation receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713292.2A GB9713292D0 (en) 1997-06-25 1997-06-25 Novel cation receptor
GB9713292.2 1997-06-25

Publications (1)

Publication Number Publication Date
WO1999000394A1 true WO1999000394A1 (en) 1999-01-07

Family

ID=10814830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001854 WO1999000394A1 (en) 1997-06-25 1998-06-24 Calixarene tubes as cation receptors

Country Status (7)

Country Link
US (1) US6326394B1 (en)
EP (1) EP0993462B1 (en)
JP (1) JP2001515515A (en)
AT (1) ATE229959T1 (en)
DE (1) DE69810294T2 (en)
GB (2) GB9713292D0 (en)
WO (1) WO1999000394A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042104A2 (en) * 2004-10-04 2006-04-20 Regents Of The University Of Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091338B2 (en) * 2001-11-15 2006-08-15 Pg Research Foundation Purification of 4,4′(5′)- di-t-butylcyclohexano-18-crown-6
KR100411495B1 (en) * 2001-12-06 2003-12-18 한국수력원자력 주식회사 Novel n-phenyl calix[4]crown azacrown derivatives and their preparation
US7790377B2 (en) * 2003-08-29 2010-09-07 The University Of North Carolina At Greensboro Compounds that act to modulate insect growth and methods and systems for identifying such compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012502A1 (en) * 1992-11-26 1994-06-09 Commissariat A L'energie Atomique Bis-crown calix[4]arenes, method for preparing same and use thereof for selectively recovering cesium and actinides
JPH06201639A (en) * 1992-12-28 1994-07-22 Res Dev Corp Of Japan Ion selective electrode using light responsive calix arene derivative
WO1994024138A1 (en) * 1993-04-19 1994-10-27 Commissariat A L'energie Atomique Calix|4|arene crown ethers, method for preparing same, and use thereof for the selective extraction of caesium and actinides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012502A1 (en) * 1992-11-26 1994-06-09 Commissariat A L'energie Atomique Bis-crown calix[4]arenes, method for preparing same and use thereof for selectively recovering cesium and actinides
JPH06201639A (en) * 1992-12-28 1994-07-22 Res Dev Corp Of Japan Ion selective electrode using light responsive calix arene derivative
WO1994024138A1 (en) * 1993-04-19 1994-10-27 Commissariat A L'energie Atomique Calix|4|arene crown ethers, method for preparing same, and use thereof for the selective extraction of caesium and actinides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.M. KING ET AL.: "A Highly Selective Chromoinophore for Potassium Based upon a Bridged Calix[4]arene", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, 1992, LETCHWORTH GB, pages 582 - 5584, XP002081509 *
DATABASE WPI Week 9434, Derwent World Patents Index; AN 94-273708, XP002081510 *
E. GHIDINI ET AL.: "Complexation of Alkali Metal Cations by Conformationally Rigid, Stereoisomeric Calix[4]arene Crown Ethers: A Quantitative Evaluation of Preorganization", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 112, no. 19, 1990, DC US, pages 6979 - 6985, XP002081508 *
G.G. GOKEL ET AL.: "Synthetic Organic Chemical Models for Transmembrane Channels", ACCOUNTS OF CHEMICAL RESEARCH., vol. 29, no. 9, 1996, WASHINGTON US, pages 425 - 432, XP002081507 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042104A2 (en) * 2004-10-04 2006-04-20 Regents Of The University Of Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making
WO2006042104A3 (en) * 2004-10-04 2007-01-18 Univ Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making
US8207228B2 (en) 2004-10-04 2012-06-26 Regents Of The University Of Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making
US8642656B2 (en) 2004-10-04 2014-02-04 Regents Of The University Of Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making
US8716343B2 (en) 2004-10-04 2014-05-06 Regents Of The University Of Minnesota Calixarene-based peptide conformation mimetics, methods of use, and methods of making

Also Published As

Publication number Publication date
DE69810294T2 (en) 2003-09-25
GB9713292D0 (en) 1997-08-27
EP0993462A1 (en) 2000-04-19
GB2342351B (en) 2001-08-22
GB2342351A (en) 2000-04-12
ATE229959T1 (en) 2003-01-15
GB9927551D0 (en) 2000-01-19
JP2001515515A (en) 2001-09-18
DE69810294D1 (en) 2003-01-30
US6326394B1 (en) 2001-12-04
EP0993462B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
Casnati et al. Bridged calix [6] arenes in the cone conformation: new receptors for quaternary ammonium cations
Nicolaou et al. Designed enediynes: a new class of DNA-cleaving molecules with potent and selective anticancer activity
Behr et al. Molecular receptors. Functionalized and chiral macrocyclic polyethers derived from tartaric acid
Senge et al. Comparative analysis of the conformations of symmetrically and asymmetrically deca-and undecasubstituted porphyrins bearing meso-alkyl or-aryl groups
Luengo et al. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface
Toda et al. Optical resolution of binaphthyl and biphenanthryl diols by inclusion crystallization with N-alkylcinchonidium halides. Structural characterization of the resolved materials
Frkanec et al. Calix [4] arene Amino Acid Derivatives. Intra‐and Intermolecular Hydrogen‐Bonded Organisation in Solution and the Solid State
Arduini et al. Synthesis of 1, 2-bridged calix [4] arene-biscrowns in the 1, 2-alternate conformation
Gu et al. Synthesis, cytotoxic evaluation and DNA binding study of 9-fluoro-6 H-indolo [2, 3-b] quinoxaline derivatives
CN116143842A (en) Cyclometaliridium complex of oxidized iso-aporphine alkaloid and N-heterocyclic carbene, and synthetic method and application thereof
EP0993462B1 (en) Calixarene tubes as cation receptors
CN110452283B (en) Anti-tumor quaternary ammonium salt derivative and preparation method and application thereof
Nekvinda et al. Chemistry of cobalt bis (1, 2-dicarbollide) ion; the synthesis of carbon substituted alkylamino derivatives from hydroxyalkyl derivatives via methylsulfonyl or p-toluenesulfonyl esters
KR20170018822A (en) Lobaplatin crystal, preparation method and pharmaceutical application
Dovesi et al. Functionalizable Alkylidenes: Tungsten Complexes of Phosphanyl‐, Amino‐, Alkynyl‐, and Tinalkylidenes and Their Dimetallic Derivatization
CN112521408A (en) Bisindole alkaloid compound and preparation method and application thereof
Brehm et al. Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions
CN109053725B (en) 2- (tetrahydroquinoline-6-yl) -tetrahydro-1, 8-naphthyridine compound and preparation method and application thereof
Chartres et al. New heterotopic, linked macrocyclic systems derived from selectively protected macrocycles
CN112480129B (en) Polycyclic spiroindoline compound containing guanidyl structural unit and preparation method and application thereof
Jursic et al. Preparation of 5-diaminomethylenebarbiturates by barbituric acid addition to carbodiimides
CN104592200A (en) Chiral paramagnetic probe using 1,4,7,10-tetraazacyclododecane as skeleton
Chu et al. Toward the design of an RNA: DNA hybrid binding agent
Nicolaou et al. Methyl 4‐Hydroxy‐5‐iodo‐2, 3‐dimethoxy‐6‐methylbenzoate: The Aromatic Fragment of Calichemicin γ. Synthesis, X‐Ray Crystallographic Analysis, and Properties
Tominaga et al. Co-Inclusion of cyclic ethers and chloroform by a macrocycle with benzophenone-3, 3′, 4, 4′-tetracarboxylic diimide units

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: GB

Ref document number: 9927551

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998930943

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999505375

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998930943

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09446458

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 1998930943

Country of ref document: EP